Loading
In the minority of pancreatic cancers without a KRAS mutation, adding the EGFR antibody nimotuzumab to gemcitabine helped people live longer, and China approved it in 2023.
NOTABLE randomised patients in China with KRAS wild-type locally advanced or metastatic pancreatic cancer to nimotuzumab or placebo with gemcitabine. Overall survival, the primary endpoint, was longer with nimotuzumab, with the benefit concentrated in patients who had not had biliary obstruction. On this trial China's regulator approved nimotuzumab for KRAS wild-type pancreatic cancer in 2023, the first EGFR-directed approval in the disease since erlotinib.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Restricted mean survival time 18.05 vs 11.14 months, ratio 0.62 (95% CI 0.40-0.97), p = 0.036; 82 eligible KRAS wild-type patients in the full analysis set
SourceShares Nimotuzumab, Metastatic pancreatic ductal adenocarcinoma.
Shares Nimotuzumab, Metastatic pancreatic ductal adenocarcinoma.
Shares Nimotuzumab, Metastatic pancreatic ductal adenocarcinoma.
Shares Nimotuzumab, Metastatic pancreatic ductal adenocarcinoma.
Shares Nimotuzumab, Metastatic pancreatic ductal adenocarcinoma.
Shares KRAS wild-type pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Nimotuzumab, Metastatic pancreatic ductal adenocarcinoma.
Shares Nimotuzumab, Metastatic pancreatic ductal adenocarcinoma.